| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, ISO 9001, USP, BP |
| Suitable for: | Elderly, Adult |
| State: | Powder |
| Purity: | >98% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Pirfenidone |
| CAS | 53179-13-8 |
| Appearance | White crystalline powder |
| MF | C12H11NO |
| MW | 185.22184 |
| Purity | 99% |
| Shelf Life | 2 Years |
Pirfenidone (PFD) is a new pyridone compound with broad-spectrum anti-fibrotic effect, which can prevent and reverse the formation of fibrosis and scarring; it was launched by Shionogi, Japan in 2008 and has been obtained. Approved by the U.S. Food and Drug Administration, it is the first drug that has demonstrated a certain efficacy in idiopathic pulmonary fibrosis (IPF) through repeated, randomized, placebo-controlled phase III clinical trials; Fibrosis, liver fibrosis and other fibrotic diseases also have good curative effect; at the same time, kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I multiple neurofibroma, adolescent I It is widely used in phase II clinical studies of multiple neurofibromas and plexiform neurofibromas, diabetes with kidney disease, and uterine leiomyoma.
1. Inhibit collagen synthesis.
2. Anti-inflammatory effect
3. Antioxidant effect
1. Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease with unknown cause, poor prognosis and high mortality. PFD is an anti-inflammatory and anti-fibrotic agent that can be used in the treatment of IPF.
2. Liver Fibrosis
3. Renal fibrotic disease
4. Multiple Sclerosis Multiple sclerosis (multiplesclerosis, MS) is an inflammatory and demyelinating disease related to the central nervous system and immunity. The related immune factors are the activation of astrocytes, glial cells, endothelial cells and the increase of lymphocytes, while PFD has the properties of inhibiting cell activation.
5. Myocardial tissue fibrosis Cardiovascular diseases such as hypertension, cardiomyopathy and atrial fibrillation can lead to myocardial tissue fibrosis, which in turn worsens or develops the disease. Treatment of cardiomyopathy caused by progressive pseudohypertrophic muscular dystrophy with PFD inhibits myocardial fibrosis and improves cardiac function. PFD reduces myocardial remodeling and atrial fibrillation by inhibiting fibrosis.
6. Neoplastic diseases: neurofibromas, uterine leiomyomas, malignant gliomas. 7. Prevention of fibrosis after organ transplantation
8. Rheumatoid Arthritis
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}